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Keynote Lecture Series

Mitral valve-in-valve and valve-in-ring: tips, tricks, and outcomes
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Transcatheter aortic valve implantation is now a mainstay of treatment in patients with aortic stenosis who
are considered intermediate, high and prohibitive risk for surgery. Extended use of this innovative platform
in treating other conditions has led to its approval in treating degenerated aortic bioprosthesis. Similarly,
use of transcatheter devices in treating degenerated mitral bioprosthesis and failed mitral valve repairs with
annuloplasty rings has opened a potential alternative to surgery in these patients. Experience in mitral valvein-valve (MVIV) and valve-in-ring (VIR), while still limited, is on the rise. Although similar in many ways to
the aortic VIV, it is different with respect to patient selection, planning and procedural steps. Familiarity with
the bioprosthetic properties and dimensions can help an operator choose an appropriate transcatheter device
and deploy it in an ideal position. Due to greater variability in construction and properties, mitral rings
have led to poorer results compared to mitral valve-in-valve. Understanding the properties of mitral rings is
critical and has been simplified by us in a stepwise manner. We also describe steps in patient preparation and
procedure, which should help operators in performing this procedure. Certain unique complications, such
as left ventricular outflow tract obstruction and risk of embolization, are discussed with tips to address these
issues. Once these steps are followed, the procedure can be performed with minimal risk and good outcome.
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Introduction
Mitral valve replacement and repair have formed the
backbone of mitral surgery in the last few decades. Mitral
pathology varies from degenerative and ischemic, which
are commonly seen in the western world, to rheumatic
heart disease, which is predominantly seen in developing
countries (1). Mitral valve repair is preferred over
mitral valve replacement, as it has shown to be a better
prognostic procedure and also postpones the need for
a replacement in relatively younger patients (2). This is
important, as we do not have an ideal valve replacement
substitute for replacement. In younger patients, mechanical
valves are preferred, as they can last lifelong but require
anticoagulation, whereas in older patients, a bioprosthesis
(pericardial or porcine) valve is preferred to eliminate the
need for anticoagulation. Bioprosthetic valves, however,
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degenerate with time, and durability varies from 10 to
15 years in the mitral position (3). Importantly, younger
patients are also observed to favor bioprosthetic valves,
which means that more patients will likely need subsequent
intervention (4). Until recently, redo-surgery was the
only option for these patients, but with the success of
transcatheter aortic valve replacement (TAVR) and valvein-valve (VIV) for degenerated aortic bioprosthesis, an
alternative of mitral valve-in-valve (MVIV) has emerged (5).
While similar in many ways, MVIV has certain specific
unique aspects with respect to patient selection, procedure
planning and postoperative care. Interestingly, as the
number of mitral repairs for various pathologies has
increased, the number of failures has also risen. Failure can
be due to pathology, complexity of repair and/or technical
reasons. One of the key elements of any mitral repair is
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annuloplasty. Annuloplasty is performed to reshape and
stabilize the mitral annulus and is achieved by suturing an
annuloplasty ring/band to the mitral annulus on the atrial
side. Broadly, the annuloplasty can be just posterior, as well
posterior and anterior, to achieve this. A variety of mitral
rings have been manufactured and implanted in the last two
decades. Similar to the concept of MVIV, repair failures
have been treated by implanting a TAVR device within a
ring, which is referred to as mitral valve-in-ring (MVIR) (6).
However, MVIV and MVIR are more challenging
procedures compared to TAVR in native valve and aortic
VIV. Although MVIV and MVIR share multiple similarities,
MVIR is a much more complex procedure than MVIV. In
this article, we describe optimal patient selection for MVIV
and MVIR, along with a step-by-step approach to both
procedures, and discuss possible complications, outcomes,
and tips on postoperative care. Some aspects of planning
and procedural steps are similar in both MVIV and MVIR
and will be described together, while important differences
will be discussed separately in detail to help operators plan
for optimal results.
Operative technique
Procedural planning—MVIV
Identification of the bioprosthesis (MVIV)
The first step is to identify the type and size of bioprosthesis.
In the mitral position, unlike the aortic position, only
stented bioprosthesis are used. Details of the bioprosthesis,
such as type and size, can be obtained from the operation
note, valve card given to the patient, or from the
bioprosthesis manufacturer. If this information is not
available, the bioprosthesis can be identified from its
fluoroscopic appearance (7). The fluoroscopic appearance
of each bioprosthesis is unique and is similar to its aortic
counterpart (Figure 1).
True internal diameter
Once the type of the bioprosthesis is identified, the next
step is to determine the “true internal diameter (ID)” (8).
Manufacturer labeling provides label size, external stent
diameter and stent internal diameter. However, these
parameters may be misleading when planning a MVIV. True
ID is the most important dimension and determines the
size of the transcatheter heart valve (THV) to be implanted
within a given bioprosthesis. True ID is essentially the
mechanical internal diameter after mounting the leaflets
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on the stent frame (Figure 2) (8). This information can be
easily obtained from the MVIV App (Figure 3) (9). While
computerized tomography scan (CT) is emerging to be
an important imaging modality, CT characterization of
different bioprostheses is far from standardized; hence,
CT scans can only be used as an adjunct to the sizing
information in the MVIV App.
THV type and size
A THV is selected on the basis of user preference and
access route. It is obvious that only THV devices with
short profiles can be used in the mitral position (Figure 4).
The most experience has been with the SAPIEN balloon
expandable platform (SAPIEN, SAPIEN XT and SAPIEN
3, Edwards Lifesciences, Irvine USA). Other THV devices
used are INNOVRE, MyVal, Lotus and Direct Flow (10).
Size of the THV used is determined by the sizing algorithm
of each device. In the MVIV, an at least 2 mm oversize over
the True ID is preferred due to higher closing pressures
and risk of embolization. Excessive oversizing may be
unfavorable, as it leads to under expansion of the THV
device. Under expansion increases the risk of leaflet pin
wheeling, possible thrombosis, or decreased durability.
Fluoroscopic appearance
While important to identify the type of the device,
important fluoroscopic landmarks for ideal positioning
of the THV device during the procedure must also
be identified. An ideal position can be defined as a
position where the device is secure and achieves best
hemodynamic performance (11). Hence, the neo-annulus
of the bioprosthesis, which is the narrowest portion of
the bioprosthesis, should be identified. The neo-annulus
corresponds to the sewing ring of the bioprosthesis. Some
bioprostheses display a sewing ring marker, but in some
bioprostheses where the stent frame or stent post markers
are visible, identifying the neo-annulus can be tricky
(Figure 5). It is then important to know the relationship
between the stent frame/stent post markers and the sewing
ring to achieve ideal positioning, which is available in the
Mitral VIV app.
Procedural planning—MVIR
Unlike MVIV, MVIR is much more complex due to varying
types of rings. It may or may not be easy to identify each
ring directly from its fluoroscopic appearance; hence,
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Figure 1 Surgical bioprosthetic mitral valves and their fluoroscopic appearance. (A) Carpentier-Edwards standard porcine; (B) CarpentierEdwards SAV porcine; (C) Epic or Biocor porcine; (D) Hancock II porcine; (E) Mosaic porcine; (F) Perimount Pericardial; (G) Magna
Pericardial; (H) Pericarbon More Pericardial.
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Figure 2 Dimensions of a surgical bioprosthetic valve and true internal diameter (ID). (A) Inflow aspect of the bioprosthesis of a pericardial
valve (dimension A: stent frame outer diameter, dimension B: stent frame inner diameter and dimension D: external diameter of sewing
ring). (B) Effect of porcine leaflets on ID, stent ID is reduced by at least 2 mm (true ID porcine valves = stent ID – 2 mm). (C) Effect of
pericardial leaflets on ID, stent ID is reduced by at least 1 mm (true ID pericardial valves = stent ID − 1 mm)

Figure 3 Valve in Valve mitral app: figure demonstrates the App icon and various panels in the workflow. Important information such as
valve, ring type, and dimensions (including True ID, size of THV recommended, ideal positioning) are available in the App.

information obtained from the manufacturer and operative
note is critical. Some rings, however, are unique in their
appearance and can be identified easily (Figure 6). Once
identified, it is important to determine suitability of the ring
for the MVIR procedure, as, unlike MVIV, not all rings are
suitable.
Rings can be classified as: (I) complete, nearly complete
or incomplete; (II) rigid, semirigid or flexible. For reason of
simplicity, complete and nearly complete will be grouped
together as complete.
The four important properties to be considered are:
(I) ability to become circular; (II) ability to provide good
anchor; (III) size of the ring; (IV) radio-opacity.

© Annals of Cardiothoracic Surgery. All rights reserved.

Circularity
Construction and components of the ring can be used to
determine achievement of circularity. Incomplete rings/
band obviously cannot become circular due to an absent
anterior portion (Figure 7A). A complete ring on the other
hand may or may not become circular depending on its
components. Rigid rings by nature of their constructions
cannot become circular (Figure 7B), semirigid rings can
become circular/nearly circular and flexible rings can
become circular (Figure 7C). When a ring cannot become
circular, the THV is either going to be under expanded
or become deformed, resulting in a suboptimal result
(Figure 7B).

Ann Cardiothorac Surg 2021;10(1):96-112 | http://dx.doi.org/10.21037/acs-2019-mv-169

Pirelli et al. Mitral valve-in-valve and valve-in-ring

100

A

B

C

D

E

F

Figure 4 Various transcatheter heart valves (THV) used in mitral position. (A) SAPIEN; (B) SAPIEN XT; (C) SAPIEN 3; (D) Lotus;
(E) Directflow; (F) Myval.

Figure 5 Neo-annulus of surgical bioprosthesis and its relationship with fluoroscopic markers. Narrowest portion of the valve is at the
sewing ring level. (A) Mosaic mitral valve: the markers are in the stent post (white arrows), which are at different levels compared to the
sewing ring level (black arrows). This may make ideal positioning of a transcatheter valve challenging. (B) Epic mitral valve: the markers
are in the sewing ring (white arrows) and hence at the same level of the sewing ring (black arrows). This makes ideal positioning of a
transcatheter valve easy.

This is very important as poor results can simply be
avoided by not performing MVIR in rigid rings. There can
be some exceptions, such as rigid rings with a small gap in

© Annals of Cardiothoracic Surgery. All rights reserved.

the anterior portion (Figure 7D), which may develop decent
immediate results due to deflection of the gap but will
definitely not maintain good mid-term or long-term results.
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Figure 6 Mitral rings and their fluoroscopic appearance. (A) Profile 3D, Medtronic Inc.; (B) Rigid saddle, Abbott St. Jude; (C) Annuloflo,
Livanova; (D) Classic, Edwards Lifesciences; (E) IMR Etiologix, Edwards Lifesciences; (F) Geoform, Edwards Lifesciences; (G) Memo 3D,
Livanova; (H) Physio 1, Edwards Lifesciences; (I) Physio 2, Edwards Lifesciences; (J) Seguin, Abbott St. Jude; (K) CG Future, Medtronic
Inc.; (L) Annuloflex, Livanova; (M) Duran Ancore, Medtronic Inc.; (N) Sovering, Livanova; (O) Tailor ring/band, Abbott St. Jude; (P)
Simulus semirigid ring, Medtronic Inc.

Anchoring
Although a ring may be able to become circular, it also needs
to provide a secure anchor. Without proper anchoring, the
THV will embolize. Anchoring is dependent on the rigidity
and dimensions. Incomplete rings cannot provide a good
anchor. On the other hand, complete rings, depending on
their construct, can provide a good anchor. If a ring is too
flexible, it can become circular but will not provide a good
anchor. Alternatively, a rigid ring can provide a good anchor
but does not become circular. Semirigid rings are best of
both and provide good anchor, as well as having the ability
to become circular or nearly circular. Similarly, flexible
rings of certain sizes can also provide good anchor even
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when stretched, providing enough margin for oversizing.
Size of the ring and dimensions
The smallest and largest THV available are size 20 and
29, respectively. Hence, choosing the correct size, as
well as determining if the ring is too small or large for
current THV devices, is important. This is more critical
in MVIV and is an area of immense confusion. Rings are
usually manufactured from label size 28 to 40, but some
are available in smaller or larger sizes. Furthermore, label
size definitely does not correspond to any meaningful
dimension, and the same label size rings across various types
have varying dimensions. Common dimensions provided

Ann Cardiothorac Surg 2021;10(1):96-112 | http://dx.doi.org/10.21037/acs-2019-mv-169

Pirelli et al. Mitral valve-in-valve and valve-in-ring

102

A

B

C

D

Figure 7 Ability of rings/bands to become circular is critical in influencing success of VIR procedure. (A) Incomplete band does not have
anterior support and is hence not suitable. (B) Rigid ring complete cannot become circular and can result in incomplete THV expansion,
deformation and leak. (C) Semi-rigid ring complete can become circular or nearly circular and is hence ideal for VIR. (D) Rigid ring
complete is very similar to rigid ring complete, but the open ends may allow greater degree of circularity to give acceptable results in some
cases. VIR, valve-in-ring.
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by the manufacturers are commissure-to-commissure (CC)
length, septal-lateral (SL) length, area, and perimeter. Not
all manufacturers provide these dimensions. Additionally,
most mitral rings are kidney shaped and become circular or
nearly circular after MVIR, resulting in different area and
diameter. Therefore, it is important for the user to refer
to the MVIV app to determine suitability, as some rings
may be too large for a given ring. Usually, any ring larger
than label size 34 is not suitable for VIR. With flexible
rings, one should also measure the CT dimensions of an
imaginary circle and take into consideration the degree of
ring extension and malleability to determine suitability.
Radio-opacity
Rings that are easily seen will make the procedure easier.
Rings that are not well seen will need trans-esophageal
echo, as well as certain level of experience during the
procedure (Figure 6J,O). To summarize, when considering
a patient for MVIR, determination of suitability should
consider the four properties discussed above. Table 1
summarizes the different ring options, their properties, and
suitability for a MVIR procedure.
Risk of complications
Left ventricular outflow tract obstruction
Left ventricular outflow tract obstruction (LVOTO) is
the Achilles heel of any transcatheter mitral intervention.
Once a THV is implanted during MVIV or MVIR, the
THV pins open the prosthetic or native leaflet to possibly
introduce LVOTO (Figure 8A,B). Furthermore, the
THV is now covered partially or fully by these leaflets,
and blood flow through the THV stent into the LVOT
is not feasible (Figure 8C,D). Many factors determine risk
and degree of LVOTO (Figure 9). The degree of residual
LVOT dimensions (neo-LVOT) which is acceptable
remains unclear (12,13). The risk for LVOTO is higher
after MVIR than MVIV. The risk is more prominent for
pericardial valves than porcine and for taller valves than
shorter. It is important to stress the implication of this
single complication, as LVOTO correlates with poor
outcome; therefore, LVOTO prevention is better than
attempts to treat post-operational LVOTO. CT analysis
to determine neo-LVOTO is critical. Such patients should
be reconsidered for surgery. In some patients where the
surgical option is not feasible, strategies such as alcohol
septal ablation or LAMPOON can be attempted (14).
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THV embolization
One of the unique complications in MVIV and VIR is THV
embolization. The systolic pressure creates closing pressures
on the mitral valve and is considerably higher than closing
pressures observed in the other three valve positions.
Reports of immediate, early, and delayed embolization
were not uncommon in the early experience of this therapy
area (15). Correct oversizing using the True ID hence
remains critical. To avoid embolization, it is important to
avoid parallel deployment (Figure 10A,B) and to achieve
conical deployment (Figure 10C,D).
Access routes
Three routes have been described for various devices:
transapical (TA), trans-septal (TS) and trans-atrial (Ta)
(Figure 11). The majority of the early cases were performed
by TA approach, but TS is now the predominant approach
due to its less invasive nature. Certain THV, however, can
only be implanted through the TA approach, such as Lotus
and Directflow. The SAPIEN family of THV and MyVal
on the other hand can be implanted through either of the
approaches. Both TA and TS approaches will be described
in detail later.
Preparation
The procedure should be performed in a hybrid or a
well-equipped catheter laboratory with facilities for
hemodynamic support and, if needed, open heart surgery
for bail out. A clear plan in terms of bail out and equipment
needed should be available. Risk of embolization and
serious complications such as left ventricular perforation
and significant LVOTO are rare but can be life threatening
if the bailout plan is unclear.
The procedure should be performed under general
anesthesia with transesophageal echocardiography (TEE)
guidance. TEE provides excellent imaging guidance during
the procedure and can also help rule out or diagnose left
atrial thrombus and para-valvular leak if present. In certain
cases, such as a mitral ring not visible under fluoroscopy,
TEE is the main imaging modality to guide and confirm
ideal implant position. TEE can also help to check post
implant gradients, valve function and pericardial effusion
and assess LVOTO.
Once the TEE probe is inserted and central lines are
secured, defibrillation pads are placed. Before preparing the
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Medtronic

Livanova

Edwards
Lifesciences

Complete
Complete
Complete
Complete

Profile 3D (rigid)

CG Future (semi-rigid)

Duran AnCore (flexible)

Complete

3D Memo (semi-rigid)

Simulus Semi Rigid ring
(semi-rigid)

Complete

Annuloflex (semi-rigid)

Incomplete

Nearly complete

Annuloflo (rigid)

Simulus Band (flexible)

Complete

Complete

Geoform (rigid)

Sovering (flexible)

Complete

Complete

Physio 2 (semi-rigid)

IMR ETlogix (rigid)

Complete

Physio 1 (semi-rigid)

Complete

Incomplete

Cosgrove Band (flexible)

Myxo (rigid)

Nearly complete

Complete

Rigid Saddle (rigid)

Classic CE (rigid)

Complete

Complete

Complete/nearly
complete/incomplete

Seguin (semi-rigid)

Abbott St Jude Tailor band/ring (flexible)

Manufacturer

Yes

Yes

No

Yes

Yes

Yes

Yes

No

Yes

No

No

No

Yes

Yes

Yes

No

No

Yes

Yes

Circularity

Table 1 List of mitral rings, manufacturer, properties, and suitability for MVIR

No

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

No

Anchoring

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Well seen

Yes

No

Yes

Radio-opacity

23, 25, 27, 29, 31, 33, 35

24, 26, 28, 30, 32,
34, 36, 38, 40

24, 26, 28, 30, 32,
34, 36, 38, 40

24, 26, 28, 30, 32,
34, 36, 38, 40

24, 26, 28, 30, 32,
34, 36, 38, 40

24, 26, 28, 30, 32, 34, 36, 38

26, 28, 30, 32, 34, 36

26, 28, 30, 32, 34, 36

26, 28, 30, 32, 34, 36, 38. 40

26, 28, 30, 32

24, 26, 28, 30, 32, 34

30, 32, 34, 36, 38, 40

24, 26, 28, 30, 32,
34, 36, 38, 40

24, 26, 28, 30, 32,
34, 36, 38, 40

26, 28, 30, 32, 34, 36, 38

26, 28, 30, 32, 34, 36, 38, 40

24, 26, 28, 30, 32, 34

24, 26, 28, 30, 32,
34, 36, 38, 40

25, 27, 29, 31, 33, 35

Sizes

Yes, small sizes only

Yes

No

Yes

No

Yes

Yes

No

Yes, smaller sizes only

No

No

No

Yes

Yes

No

No

No

Yes

No, if band; yes, if ring

Suitability for VIR

104
Pirelli et al. Mitral valve-in-valve and valve-in-ring

Ann Cardiothorac Surg 2021;10(1):96-112 | http://dx.doi.org/10.21037/acs-2019-mv-169

Annals of cardiothoracic surgery, Vol 10, No 1 January 2021

A

B

105

C

D

Figure 8 Effect of VIV and VIR on left ventricular outflow tract (LVOT). (A) Following VIR, the anterior mitral leaflet covers the THV
and is pushed towards LVOT. (B) Following VIV, the surgical bioprosthetic leaflets cover the THV and can cause varying degrees of
obstruction to LVOT. (C) Porcine mitral valve leaflet covering the SAPIEN valve. (D) Pericardial mitral leaflets covering the SAPIEN valve.
The pericardial leaflets tend to be taller and tend to cover the THV more than the porcine counterparts. VIV, valve-in-valve; VIR, valve-inring; THV, transcatheter heart valve.

access site, fluoroscopic view for deployment is obtained.
This step is critical, as the majority of the mitral procedures
require a steep RAO view. In the fluoroscopic view, one
has to confirm that radio-opaque objects such as ECG
leads, wires, or other objects are not overlapping the field
of interest. This can complicate the procedure if detected
later. The view also allows the operators to understand their
positions during the procedure. This is critical during a
TA procedure as RAO views may interfere with the ability
of the TA operator to stand close to the patient. Once this
is confirmed, the patient is prepped for the surgery and
draped. It is our practice to prepare the surgical site from
neck to groin so as to provide access for TA route, TS route
and median sternotomy if needed.
Operation
The TS approach is described in detail using a SAPIEN
3 valve, as it is the most common approach used today.
Important steps for TA approach will be described
separately.
Access site preparation
TS approach is performed through right or left femoral
venous access. Right is preferred over the left as it allows

© Annals of Cardiothoracic Surgery. All rights reserved.

a straighter trajectory for septal puncture. An additional
venous access is secured through the left femoral vein with
an 8-Fr sheath to insert a transvenous pacing wire, which is
positioned in the right ventricle. Care is taken during the
placement of the pacing wire. The threshold is checked and
the pacing wire is secured with a stitch. A 5-Fr arterial line
is secured if needed.
Deployment view
An ideal deployment view is obtained for easier positioning
of the THV. Examples of ideal deployment view for
bioprosthetic valve and ring is shown in Figure 12. Some
valves and rings are difficult to visualize, and it is important
that the plane is identified clearly during this process.
Trans-septal puncture, septal dilatation, and valve crossing
(Video 1)
The site of the TS puncture is critical. Unlike some other
mitral valve procedures, an ideal puncture for MVIV and
MVIR is posterior-inferior (Figure 13). The puncture site
should also be at least 3.5 cm from the mitral valve annulus.
Puncture is performed under x-plane using TEE guidance,
which also ensures that there is no inadvertent injury to
aorta or cardiac perforation.
There are various kits available for TS puncture. The
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Figure 9 Factors influencing LVOTO after mitral VIV and VIR. (A) Depth of implant: the deeper the THV, the higher the LVOTO (b > a);
(B) Flare in the left ventricle: increase in flare results in higher LVOTO (d > c); (C) Aorto-mitral annular angle: the less obtuse the angle, the
higher risk of LVOTO (f > e); (D) Septal bulge: large septal bulge increases the risk of LVOTO (h > g).
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Figure 10 Risk of transcatheter heart valve embolization following mitral VIV. (A,B) Risk of embolization is high after parallel deployment;
(C,D) risk of embolization is low or none after conical deployment. VIV, valve-in-valve.

commercially available Bayliss set is commonly used. Once
the puncture is obtained, a guidewire is placed within the
left atrium. Over the guidewire, a steerable guide catheter is
placed and bent towards the mitral valve. This combination
of various catheters and guidewires allows the operator
to cross the mitral valve. The catheter is then advanced
into the left ventricle, and a stiff wire (can be pre-shaped)
is placed to provide support to deliver the THV. Various
wires commonly used according to operator preference are
Confida, Safari, Amplatz extra-stiff and Lunderquist. The
septum is now dilated with 12 or 14 Fr Balloon to facilitate
passage of the delivery system. Once the balloon is full, it
should be flossed over to confirm adequacy of septostomy.
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Once confirmed, balloon and steerable catheter are
removed, and the E-sheath is inserted.
Valve placement (Video 1)
The Commander system is used for the TS approach. The
most important part of this procedure is to check “correct
orientation” of the SAPIEN 3 device. It is the exact reverse
of the trans-femoral approach for native aortic valve
(Figure 14). The delivery system is inserted with manufacturer
logo oriented downwards, which ensures the direction of
the flexion of the delivery system is towards the mitral valve
(again exactly opposite of the TAVI procedure). The valve
is pushed out of the sheath, aligned on the catheter, and
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B

C

Figure 11 Access routes for mitral VIV and VIR. (A) Trans-septal approach: least invasive and most common; (B) trans-apical approach:
more direct and allows for better control; (C) trans-atrial approach: used during open surgical implants. VIV, valve-in-valve; VIR, valve-inring.

then advanced through the septum into the left side of the
heart. Once across, the flex catheter is retracted to expose
the proximal balloon. Care is taken to ensure that the flex
catheter still remains on the left side if possible. The valve
is advanced through the bioprosthesis. The wire is managed
so that it does not buckle or cause injury to the left
ventricle. The valve is positioned as described earlier. TEE
can be used to confirm ideal position. THV can be at an
angle during initial positioning, but as the balloon inflates,
THV tends to self-center.
Valve deployment (Video 1)
The final valvular deployment was assessed and considered
appropriate, with 3-4 mm of the transcatheter prosthesis
protruding into the left atrium for adequate stability and
optimal sealing.
Valve deployment is performed under rapid pacing.
Pacing at a rate of 180/minute eliminates ejection and
allows stable deployment. We like to perform a 2-stage
inflation, as it allows fine tuning with respect to ideal
deployment. The first stage is inflation up to 10% to 15%
followed by second stage to full deployment.
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Completion
Once the valve is deployed, the delivery system is withdrawn
partially. Valve function is assessed with TEE. Rarely, we
acquire a left ventricular angiogram. If there is a need, postdilatation is performed with same or additional volume. The
wire is then removed along with the delivery system. Shunt
across the septum is assessed by TEE. If there is residual
bidirectional or right to left shunt, the septostomy is closed
with an atrial septal defect closure device. The E-sheath is
removed, and the venous access site is closed with a single
Perclose.
Trans-apical approach
It is similar to the TA approach used for TAVR. Once the
left ventricular purse-string is placed, a guidewire is placed
across the mitral valve into the left atrium. We like to use a
softer wire to start with. Then, a catheter is placed into the
left atrium, and the softer wire is exchanged for a stiff wire,
similar to the TS approach. The Certitude system is used
for TA approach. The Certitude sheath is inserted up to the
4 cm marker and secured. In certain cases, especially MVIV
with bioprosthetic stenosis and MVIR where crossing
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D

Figure 12 Ideal deployment view of fluoroscopy is important. Deployment views are shown with: (A) Perimount valve; (B) Hancock II valve;
(C) St. Jude Rigid Saddle ring; (D) Epic/Biocor valve with SAPIEN XT positioned across it.

A

B

C

Figure 13 Trans-septal puncture for mitral VIV and VIR. (A) Schematic diagram showing fossa ovalis and the posterior-inferior site of
septal puncture (X). (B) X-plane view of trans-septal puncture under TEE, demonstrating posterior-inferior puncture (white arrows). (C)
Distance between the puncture and mitral annulus should be at least 3 cm.
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A

B

Figure 14 Orientation of the SAPIEN valve must be verified according to the approach. (A) For the Trans-septal approach using
Commander system, the skirt is loaded proximally. (B) For the Trans-apical approach using Certitude system, the skirt is loaded distally.

valve is challenging due to stenosis, we like to introduce
the sheath till the tip of the sheath is across the mitral
annular plane. Then, the dilator is removed. SAPIEN
Valve orientation is confirmed, and the delivery system
is inserted. Once the SAPIEN valve is out of the sheath
in the left atrium, the Certitude sheath is slowly backed
out until reaching the 4 cm mark. The SAPIEN valve is
now positioned and deployed, similar to the TS system.
Post deployment checks are same. Once satisfied with the
outcome, the sheath is withdrawn, often under rapid pacing,
and purse-strings are tied. Hemostasis is achieved, and the
chest is closed with a single chest drain.
Comments
Clinical results
The TMVR registry is a multicenter observational study
that collected data on THV implantation in patients with
failed mitral valve bioprosthesis, failed repair and MAC (16).
A total of 521 patients were enrolled in a 9-year period
(2009 until 2018), including 322 MVIV patients and 141
MVIR patients. The patient cohort was deemed high risk
for surgery with a mean Society of Thoracic Surgeons (STS)
score of 9% (16). A balloon expandable valve was utilized
in 90% of the cases. In terms of procedural outcomes,
conversion to surgery, need for a second valve implantation
and LVOTO, MVIR fared worse compared to MVIV.
Technical success was achieved in 94.4% of MVIV cases but
only in 80.9% of MVIR. Post-procedural MR (> moderate)
was observed more frequently in the MVIR group (18.4%
vs. 5.6%). All-cause thirty-day mortality was higher in the
MVIR cohort than the MIV cohort (9.9% vs. 6.2%). There
were no significant differences found in terms of stroke,
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major bleeding, and acute kidney injury. The authors also
demonstrated the effect of a learning curve on outcomes,
as the latter half had lower rates of complications. Another
important consideration involves valve thrombosis. This
event occurred in 10 patients after MVIV, 50% of cases
occurring within the first 3 months after the procedure,
three between 3 months and 1 year, and two after 1 year.
Overall, at 1 year, the incidence was higher in patients on
antiplatelet therapy compared to patients on anticoagulation
(60.6% vs. 1.6%; log-rank P=0.019), highlighting the
importance of anticoagulation in this subset.
Mid-term and long-term outcomes of MVIV have also
been reported by Dr. Ye and colleagues, who followed a
cohort of thirty-one patients with failed mitral bioprosthetic
valves who underwent VIV procedures with balloon
expandable valves (17). The patients with degenerated
mitral valve prosthesis had a STS score of 9.7% (high risk
for redo-surgery). The study showed overall safety and
feasibility of the transcatheter intervention, with a low rate
of major adverse events and periprocedural complications.
Thirty-day mortality and disabling stroke rates were
1.4%, rate of life-threatening bleeding was 4.1%, and no
patient had more than mild paravalvular regurgitation.
One mitral THV migrated aerially 2 months after the
procedure, causing severe paravalvular leakage (PVL).
Two patients on postoperative dual antiplatelet therapy
developed valve thrombosis, which was resolved with the
use of oral anticoagulants. Although there was just a trend
in improvement of pulmonary pressures and left ventricular
ejection fraction (LVEF) over the first 36 months, the
authors described a significant improvement in heart
failure symptoms and NYHA functional class up to 8 years.
Estimated survival rates were 88.9%, 79.5%, 69.8%, 61.9%,
and 40.5% at 1, 2, 3, 4, and 5 years, respectively.
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Results of MVIR are not as promising as MVIV (16).
Complications requiring conversion to surgery were threefold compared to VIV (2.8% vs. 0.9%), the need for a
second valve was as high as 12.1%, and LVOTO occurred
in 5% of the cases (2.2% in VIV). Paravalvular regurgitation
was common, as well as MR ≥ moderate (18.4%). VIR
showed higher mortality rates at thirty-days, greater
major bleeding events and vascular complications, higher
percentage of postprocedural acute kidney injury (AKI), and
a lower procedural success (58.2% vs. 73.6% for VIV).
Up to a few years ago, all cases of failed mitral valve
prostheses were managed surgically with redo-surgery. The
advent and development of transcatheter procedures gave
the operators a valid alternative option, especially in high
risk surgical patients. Kamioka and colleagues compared
MVIV and redo surgery in a retrospective study, analyzing
the 1-year echocardiographic and clinical outcomes.
They demonstrated that there was no difference in 1-year
mortality and thirty-days echocardiographic results, while
mitral gradients were higher in the MVIV group (7.2±2.7
vs. 5.5±1.8 mmHg), although not clinically relevant (18).
This means that good results can be achieved through a
less invasive transcatheter intervention, avoiding high risk
redo surgery. For future analysis, we need larger studies and
should also assess mid-term and long-term results to better
understand the real potential of this growing therapy area.

111

anticoagulate these patients for at least 6 months. Reported
incidence of valve dysfunction seems to be higher with
MVIV than aortic VIV.
LVOTO and risk of embolization has to be assessed
properly. Similarly, going through a checklist for suitability
of a ring is also important. If there is any doubt regarding
procedural results, the patient should be followed up
regularly with interval echocardiography.
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Advantages of MVIR and MVIR
MVIV or MVIR has following advantages: (I) avoidance of
a redo-surgery; (II) shorter operation; (III) faster recovery;
(IV) avoidance of blood transfusion.
As a result, MVIV and MVIR are slowly becoming first
line therapy in high risk surgical patients, especially through
the TS approach.
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